Is St. Jude losing the CRM battle to Boston Scientific and Medtronic?

January 28, 2010 by MedCity News

St. Jude Medical Inc. blames lower hospital spending for a drop in sales of its pacemakers and defibrillators. There's only one problem: Its main competitors, Boston Scientific Corp. and Medtronic Inc., aren't seeing the same decline.

By Thomas Lee

MedCity News logo

LITTLE CANADA, Minnesota - It’s no secret that pacemakers and defibrillators are no longer a hot growth market. Most estimates peg global sales at growing low to mid single digits for the foreseeable future.

But for St. Jude Medical Inc, (NYSE:STJ) the question remains: How much is the company to blame for its lackluster U.S. numbers?

Get the complete picture with a MassDevice Plus membership. Registered users can login here.